Optimal Vasopressin Initiation in Septic Shock
JAMA · 20.05.2025 · 333 (19) · 1688
DOI: 10.1001/jama.2025.3046 ↗Kurz gefasst
Validierungsstudie in der Zeitschrift JAMA, erschienen am 20.05.2025. Verfasst von Alexandre Kalimouttou und 7 weiteren Autor:innen. Beteiligte Einrichtung: Inserm UMR 1153, Centre for Research in Epidemiology and Statistics (CRESS), ECSTRRA Team, Université Paris Cité and Université Sorbonne Paris Nord, …. Hauptthemen laut MEDLINE: Norepinephrine, Shock, Septic, Vasoconstrictor Agents, Vasopressins. Die Arbeit wurde bisher 93-mal zitiert (Crossref) und nennt 36 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIGMS NIH HHS.
Themen: Sepsis
Abstract (Originalsprache)
Importance Norepinephrine is the first-line vasopressor for patients with septic shock. When and whether a second agent, such as vasopressin, should be added is unknown.
Objective
To derive and validate a reinforcement learning model to determine the optimal initiation rule for vasopressin in adult, critically ill patients receiving norepinephrine for septic shock. Design, Setting, and Participants Reinforcement learning was used to generate the optimal rule for vasopressin initiation to improve short-term and hospital outcomes, using electronic health record data from 3608 patients who met the Sepsis-3 shock criteria at 5 California hospitals from 2012 to 2023. The rule was evaluated in 628 patients from the California dataset and 3 external datasets comprising 10 217 patients from 227 US hospitals, using weighted importance sampling and pooled logistic regression with inverse probability weighting. Exposures Clinical, laboratory, and treatment variables grouped hourly for 120 hours in the electronic health record. Main Outcome and Measure The primary outcome was in-hospital mortality.
Results
The derivation cohort (n = 3608) included 2075 men (57%) and had a median (IQR) age of 63 (56-70) years and Sequential Organ Failure Assessment (SOFA) score at shock onset of 5 (3-7 [range, 0-24, with higher scores associated with greater mortality]). The validation cohorts (n = 10 217) were 56% male (n = 5743) with a median (IQR) age of 67 (57-75) years and a SOFA score of 6 (4-9). In validation data, the model suggested vasopressin initiation in more patients (87% vs 31%), earlier relative to shock onset (median [IQR], 4 [1-8] vs 5 [1-14] hours), and at lower norepinephrine doses (median [IQR], 0.20 [0.08-0.45] vs 0.37 [0.17-0.69] µg/kg/min) compared with clinicians’ actions. The rule was associated with a larger expected reward in validation data compared with clinician actions (weighted importance sampling difference, 31 [95% CI, 15-52]). The adjusted odds of hospital mortality were lower if vasopressin initiation was similar to the rule compared with different (odds ratio, 0.81 [95% CI, 0.73-0.91]), a finding consistent across external validation sets. Conclusions and Relevance In adult patients with septic shock receiving norepinephrine, the use of vasopressin was variable. A reinforcement learning model developed and validated in several observational datasets recommended more frequent and earlier use of vasopressin than average care patterns and was associated with reduced mortality.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Inserm UMR 1153, Centre for Research in Epidemiology and Statistics (CRESS), ECSTRRA Team, Université Paris Cité and Université Sorbonne Paris Nord, Paris, France.
- Department of Anesthesia & Perioperative Care, Zuckerberg San Francisco General Hospital and Trauma Center, University of California, San Francisco.
- Department of Anesthesiology and Intensive Care Medicine, Grenoble Alpes University Hospital, Grenoble, France.
- Department of Critical Care Medicine, School of Medicine, University of Pittsburgh, Pittsburgh, Pennsylvania.
- Center for Research, Investigation, and Systems Modeling of Acute Illness, School of Medicine, University of Pittsburgh, Pittsburgh, Pennsylvania.
- Department of Epidemiology & Biostatistics, University of California, San Francisco.
Förderung
- NIGMS NIH HHS
Zitieren
APA
Kalimouttou, A., Kennedy, J. N., Feng, J., Singh, H., Saria, S., Angus, D. C., Seymour, C. W., & Pirracchio, R. (2025). Optimal Vasopressin Initiation in Septic Shock. JAMA, 333(19), 1688. https://doi.org/10.1001/jama.2025.3046
Vancouver
Kalimouttou A, Kennedy JN, Feng J, Singh H, Saria S, Angus DC, et al. Optimal Vasopressin Initiation in Septic Shock. JAMA. 2025;333(19):1688. doi:10.1001/jama.2025.3046
BibTeX
@article{Kalimouttou2025,
author = {Kalimouttou, Alexandre and Kennedy, Jason N and Feng, Jean and Singh, Harvineet and Saria, Suchi and Angus, Derek C and Seymour, Christopher W and Pirracchio, Romain},
title = {Optimal Vasopressin Initiation in Septic Shock},
journal = {JAMA},
year = {2025},
volume = {333},
number = {19},
pages = {1688},
doi = {10.1001/jama.2025.3046}
}
EUVIMED